All the Active Ingredient Drugs
Protein Kinase Inhibitor. Brigatinib 30 mg, 90 mg. F.C. TABS.: 30. The recom. dose regimen for is: 90 mg×1/d for the first 7 days;
If 90 mg is tolerat. during the first 7 d, incr. the dose to 180 mg ×1/d.
Admin. will cont. until dis. progres. or unaccept. toxicity.
If Brigatinib is interrupt. for 14 d. or longer for reasons other than ADR's, resume tmt. at 90 mg ×1/d for 7 d. before incr. to the prev. tolerated dose.
Tmt. of pts. with anaplastic lymphoma kinase (ALK)-positive metastat. non-small cell lung cancer (NSCLC) who have progres. on or are intolerant to crizotinib.